// App-Quantinova.ai

2501 : Combination therapy with mebendazole, trametinib and metformin eliminates recalcitrant NRASQ61K melanoma cells

Researchers

Presenter

  • Maryam Abdus Samad

Principal Investigators

  • Anirudh Gaur

  • Cynthia M. Simbulan-Rosenthal

  • Edward C. McCarron

  • Dean S. Rosenthal

Medical Centers

  • Division of Surgical Oncology, The Harry and Jeanette Weinberg Cancer Institute, MedStar Franklin Square Medical Center, Baltimore, MD

  • Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • B-Raf proto-oncogene, serine/threonine kinase

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Serine/threonine-protein kinase mTOR

  • PI3K/AKT

Drug/Treatment

  • Mebendazole

  • Trametinib

  • Metformin Hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved